Trial · NCT02296190

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

NCT02296190, Phase 2, Completed, Milestone Pharmaceuticals Inc.; results first posted 2020-12-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm. Trials, record NCT02296190. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02296190

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
NCT number: NCT02296190
Status: Completed
Phases: Phase 2
Enrollment: 199 participants, actual
Lead sponsor: Milestone Pharmaceuticals Inc.
Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Etripamil, Placebo
First posted: 2014-11-20
Last updated: 2020-12-30
Results first posted: 2020-12-30

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration	Within 15 minutes of study drug administration	The primary efﬁcacy endpoint was the rate of successful PSVT conversion to sinus rhythm lasting at least 30 seconds within 15 minutes of study drug administration after a minimum of 5 minutes in sustained PSVT.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration	Within 15 minutes of study drug administration	The efficacy analysis was based on the Evaluable Population which included all randomized subjects who were induced and sustained Supraventricular tachycardia (SVT) for 5 minutes, received the study drug, and completed the assessment of conversion to sinus rhythm.~The Open- Label Etripamil 70 mg group was not part of the Evaluable Population, as the subjects did not meet the criteria of having sustained Supraventricular tachycardia (SVT) for 5 minutes.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration	Etripamil_140 mg	20	Participants
The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration	Etripamil_ 105 mg	15	Participants
The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration	Etripamil_70 mg	20	Participants
The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration	Etripamil_35 mg	13	Participants
The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration	Placebo	7	Participants

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Etripamil_140 mg	35
Overall Study	STARTED	Etripamil_ 105 mg	41
Overall Study	STARTED	Etripamil_70 mg	35
Overall Study	STARTED	Etripamil_35 mg	43
Overall Study	STARTED	Placebo	36
Overall Study	STARTED	Open-label Etripamil 70 mg	9
Overall Study	COMPLETED	Etripamil_140 mg	21
Overall Study	COMPLETED	Etripamil_ 105 mg	20
Overall Study	COMPLETED	Etripamil_70 mg	23
Overall Study	COMPLETED	Etripamil_35 mg	20

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events384

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nasal Discomfort	Respiratory, thoracic and mediastinal disorders	Etripamil_140 mg	8	21	8
other	Nasal Discomfort	Respiratory, thoracic and mediastinal disorders	Etripamil_105 mg	7	20	7
other	Nasal Discomfort	Respiratory, thoracic and mediastinal disorders	Etripamil_70 mg	11	23	11
other	Nasal Discomfort	Respiratory, thoracic and mediastinal disorders	Etripamil_35 mg	12	20	12
other	Nasal Discomfort	Respiratory, thoracic and mediastinal disorders	Placebo	1	20	1
other	Nasal Discomfort	Respiratory, thoracic and mediastinal disorders	Open Label Etripamil 70 mg	6	9	6
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Etripamil_140 mg	8	21	8
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Etripamil_105 mg	9	20	9
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Etripamil_70 mg	6	23	6
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Etripamil_35 mg	5	20	5

1 to 10 of 384Source ClinicalTrials.gov

See all 384 adverse events

Adverse event totals18

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Etripamil_140 mg	0	21
Total, all-cause mortality	Etripamil_105 mg	0	20
Total, all-cause mortality	Etripamil_70 mg	0	23
Total, all-cause mortality	Etripamil_35 mg	0	20
Total, all-cause mortality	Placebo	0	20
Total, all-cause mortality	Open Label Etripamil 70 mg	0	9
Total, other adverse events	Etripamil_140 mg	20	21
Total, other adverse events	Etripamil_105 mg	14	20
Total, other adverse events	Etripamil_70 mg	18	23
Total, other adverse events	Etripamil_35 mg	17	20

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30049309	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02296190

GET https://conductscience.org/api/trials/v1/NCT02296190/events?page=2

API reference For AI assistants